Drug intelligence / Profile preview

cyclophosphamide + goserelin + leuprorelin

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules, Peptides
Administration
Oral, Intravenous, Subcutaneous, Intramuscular
01

Overview

This is a combination regimen consisting of three drugs: - **Cyclophosphamide** is an alkylating agent used as chemotherapy, primarily for its cytotoxic effects on rapidly dividing cells. It crosslinks DNA, leading to cell death. - **Goserelin** and **leuprorelin (leuprolide)** are both gonadotropin-releasing hormone (GnRH) agonists. They act by initially stimulating, then downregulating the pituitary GnRH receptors, resulting in decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to suppression of ovarian or testicular steroidogenesis and a reduction in circulating estrogen or testosterone levels. The combination of these agents may be used in clinical settings where both cytotoxic chemotherapy and profound hormonal suppression are desired—such as certain breast cancers in premenopausal women for ovarian protection during chemotherapy or advanced hormone-sensitive cancers[3][6][9]. Goserelin and leuprorelin have been shown to be comparable for ovarian protection during cyclophosphamide-based chemotherapy[3].

02

Targets

DNAGnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on cyclophosphamide + goserelin + leuprorelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + goserelin + leuprorelin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call